AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
July 24, 2021
AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
nhigginsdunn
Fri, 07/23/2021 – 14:46
Read the source article at Pharma News
2021-07-23 19:30:41